Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)

3 Months Ended

Feb. 28, 2017

Stock option activity for the three months ended February 28, 2017, was as follows:


	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value


Outstanding at November 30, 2016		1,142,010		$	2.36		4.99	$	1,095,525
Granted		—			—				—
Exercised		(19,281	)		1.74				57,949
Expired/forfeited		(2,500	)		1.50				7,150

Outstanding at February 28, 2017		1,120,229		$	2.37		4.82	$	2,225,014

Exercisable at February 28, 2017		1,041,780		$	2.31		4.56	$	2,132,983

Significant Option Groups Exercisable Option and its Price and Contractual Life

Significant option groups exercisable at February 28, 2017 and related price and contractual life information are as follows:


Range of Exercise Prices	Outstanding						Exercisable
	Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Outstanding		Weighted Average Exercise Price


$1.01 to $2.00		427,500		4.65	$	1.73		427,500	$	1.73
$2.01 to $3.00		465,500		3.28	$	2.57		465,500	$	2.57
$3.01 to $4.00		227,229		8.32	$	3.18		148,780	$	3.17

		1,120,229		4.82	$	2.37		1,041,780	$	2.31

Summary of Non-Vested Options

A summary of the status of the Company’s non-vested options as of February 28, 2017, and changes during the three months ended February 28, 2017, is presented below:


	Options			Weighted Average Grant-Date Fair Value


Non-vested at November 30, 2016		97,406		$	1.84
Granted		—			—
Vested		(18,957	)		1.83
Forfeited		—			—

Non-vested at February 28, 2017		78,449		$	1.84